Literature DB >> 32419859

A Prospective Study on Prescription Pattern in Chronic Obstructive Pulmonary Disease.

D B Jyothi1, S Vijay Prasad2, Yakaiah Vangoori3, Ambadasu Bharatha4.   

Abstract

Background: Irrational prescribing results produce a negative impact on health and economy of both individuals and society, leading to wastage of resources and widespread health hazards. Method: Outpatients with mild, moderate, and severe COPD were included. Several parameters were noted: patient's age and gender, outpatient (OPD) ID number, date of admission, occupation, h/o smoking, alcohol consumption, etc, disease condition details (duration, gradation as mild, moderate and severe, and co-existing diseases), prescribed medication details (dose, frequency, route of administration, and duration). Drug selection was assessed as per GOLD guidelines, the severity of disease was categorized according to the same guidelines, and medication efficacy was evaluated by treatment outcome according to the modified MRC dyspnoea scale.
Results: Inhalation route (36.95%) was the most preferred route of drug administration in this study, followed by the parenteral route (34.34%), and enteral route (28.71%). Adherence to GOLD 2015: All patients (n=400) were categorized to Gold stages I to IV based on the severity of COPD. Amongst these patients, 11 were in stage I, 146 in stage II, 184 in stage III, and 59 in stage IV. The majority of subjects received fixed-dose combination therapy: levocetirizine + montelukast (77%) and least bromhexine + guaiphenesin + terbutaline + menthol (18%). Dyspnoea status was graded from 0 to 4 according to the modified MRC dyspnea scale. Out of the 400 patients, 18 had grade 0, 44 grade 1, 156 grade 2, 133 grade 3, and 49 grade 4.
Conclusion: Overall, data from this analysis suggest that adherence to GOLD guidelines does not have a perceivable impact on symptom prevalence, exacerbation rate or lung function. Male sex, asthma and severe co-morbidities as a cerebrovascular insult could be associated with a risk for frequent exacerbations.

Entities:  

Year:  2020        PMID: 32419859      PMCID: PMC7221280          DOI: 10.26574/maedica.2020.15.1.37

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN: 1841-9038


  13 in total

1.  Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study.

Authors:  A E M Lucas; F W J M Smeenk; I J Smeele; C P van Schayck
Journal:  Fam Pract       Date:  2008-02-27       Impact factor: 2.267

2.  How far is real life from COPD therapy guidelines? An Italian observational study.

Authors:  Antonio Corrado; Andrea Rossi
Journal:  Respir Med       Date:  2012-04-05       Impact factor: 3.415

3.  Characteristics associated with sustained abstinence from smoking among patients with COPD.

Authors:  Sandra G Adams; Jacqueline A Pugh; Lewis E Kazis; Shuko Lee; Antonio Anzueto
Journal:  Am J Med       Date:  2006-05       Impact factor: 4.965

Review 4.  Importance of inhaler devices in the management of airway disease.

Authors:  J C Virchow; G K Crompton; R Dal Negro; S Pedersen; A Magnan; J Seidenberg; P J Barnes
Journal:  Respir Med       Date:  2007-10-17       Impact factor: 3.415

5.  Associations between lung function and alcohol consumption--assessed by both a questionnaire and a blood marker.

Authors:  S Frantz; P Wollmer; M Dencker; G Engström; U Nihlén
Journal:  Respir Med       Date:  2013-09-07       Impact factor: 3.415

6.  EMPADE Study: Evaluation of Medical Prescriptions and Adverse Drug Events in COPD Patients Admitted to Intensive Care Unit.

Authors:  Mir S Adil; M Amer Khan; M Nematullah Khan; Ihtisham Sultan; M Aamer Khan; S Amir Ali; Afroze Farooqui
Journal:  J Clin Diagn Res       Date:  2015-11-01

7.  Guideline adherence in management of stable chronic obstructive pulmonary disease.

Authors:  Roozbeh Sharif; Christel R Cuevas; Yue Wang; Mohit Arora; Gulshan Sharma
Journal:  Respir Med       Date:  2013-04-30       Impact factor: 3.415

8.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.

Authors:  Don D Sin; S F Paul Man
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

9.  Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease.

Authors:  Ken-Ichiro Tanaka; Shota Kurotsu; Teita Asano; Naoki Yamakawa; Daisuke Kobayashi; Yasunobu Yamashita; Hiroshi Yamazaki; Tomoaki Ishihara; Hiroshi Watanabe; Toru Maruyama; Hidekazu Suzuki; Tohru Mizushima
Journal:  Sci Rep       Date:  2014-03-28       Impact factor: 4.379

10.  Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States.

Authors:  Gregory B Diette; Anand A Dalal; Anna O D'Souza; Orsolya E Lunacsek; Saurabh P Nagar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.